Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Alberta Investment Management Corp

Alberta Investment Management Corp decreased its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 6.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 74,290 shares of the company’s stock after selling 5,196 shares during the period. Alberta Investment Management Corp’s holdings in Moderna were worth $3,089,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Atria Wealth Solutions Inc. lifted its holdings in shares of Moderna by 27.8% in the fourth quarter. Atria Wealth Solutions Inc. now owns 7,795 shares of the company’s stock valued at $324,000 after buying an additional 1,694 shares during the period. Venturi Wealth Management LLC raised its position in Moderna by 286.2% in the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock worth $37,000 after acquiring an additional 664 shares in the last quarter. Sanctuary Advisors LLC lifted its holdings in Moderna by 14.5% in the 4th quarter. Sanctuary Advisors LLC now owns 20,987 shares of the company’s stock valued at $861,000 after acquiring an additional 2,656 shares during the last quarter. State of New Jersey Common Pension Fund D boosted its position in shares of Moderna by 2.8% during the 4th quarter. State of New Jersey Common Pension Fund D now owns 124,231 shares of the company’s stock valued at $5,166,000 after purchasing an additional 3,360 shares in the last quarter. Finally, Allworth Financial LP boosted its position in shares of Moderna by 17.3% during the 4th quarter. Allworth Financial LP now owns 1,901 shares of the company’s stock valued at $73,000 after purchasing an additional 281 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Moderna Stock Down 6.0 %

Moderna stock opened at $33.73 on Friday. Moderna, Inc. has a 12 month low of $29.25 and a 12 month high of $170.47. The company’s fifty day simple moving average is $38.17 and its 200-day simple moving average is $53.20. The stock has a market cap of $12.98 billion, a P/E ratio of -3.63 and a beta of 1.59.

Insider Activity at Moderna

In other Moderna news, insider Shannon Thyme Klinger sold 1,418 shares of the business’s stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $42.79, for a total value of $60,676.22. Following the completion of the sale, the insider now directly owns 19,717 shares of the company’s stock, valued at $843,690.43. The trade was a 6.71 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Over the last 90 days, insiders sold 2,664 shares of company stock valued at $115,210. Insiders own 15.70% of the company’s stock.

Analyst Ratings Changes

Several research firms recently commented on MRNA. Leerink Partners cut their target price on shares of Moderna from $31.00 to $27.00 and set an “underweight” rating for the company in a research note on Thursday, January 16th. HSBC raised Moderna from a “hold” rating to a “buy” rating and set a $58.00 price target on the stock in a report on Monday, November 18th. Bank of America reduced their price objective on Moderna from $41.00 to $34.00 and set an “underperform” rating for the company in a research note on Tuesday, February 11th. Wolfe Research began coverage on Moderna in a research report on Friday, November 15th. They set an “underperform” rating and a $40.00 target price on the stock. Finally, Evercore ISI decreased their price target on Moderna from $60.00 to $50.00 and set an “in-line” rating for the company in a research report on Monday, January 27th. Four analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $60.63.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.